Episode Details
Back to Episodes
Daily Roundup | GSK Kills Camlipixant: The $2B Bellus Bet Unravels
Published 6 days, 9 hours ago
Description
GSK shelved camlipixant after mixed Phase 3 data — the third P2X3 chronic cough drug to fail and a blow to its ~$2B Bellus Health deal. Plus Jasper Therapeutics' lifeline merger with Kira and a $132M raise, Novartis Fabhalta's full FDA approval in IgA nephropathy, Lilly's $2.8B AtaiBeckley psychedelics buyout, a Merck ADC lung cancer readout, and a Pfizer downgrade.
Visit us at thepharmacloseout.com.